InsiderTrades

Form 4 for ABOS Acumen Pharmaceuticals, Inc.

Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-04 · accession 0001415889-25-015836 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2025-06-05 2025-06-04 ABOS RA Capital Healthcare Fund LP Dir, 10% A - Grant $0.00 +12.8K 12.8K New $0
DI 2025-06-05 2025-06-04 ABOS RA Capital Healthcare Fund LP Dir, 10% A - Grant $0.00 +19.5K 19.5K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-06-04 A A 12,800 $0.00 12,800 I See footnotes — — (F1) Represents the grant of a restricted stock unit ("RSU") award to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of June 4, 2026 or the Issuer's 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date. (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F3) Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock.
2 Derivative Stock Option (Right to Buy) 2025-06-04 A A 19,500 $0.00 19,500 I See Footnotes $1.07 · — to 2035-06-04 19,500 Common Stock (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. (F3) Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock. (F7) Represents the grant of an option to Dr. Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of June 4, 2026 or the 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.